Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

Warehouses in the US are full of foods that fight malnutrition, while kids go hungry in places like South Sudan.

GILD jumps 27.2% in six months as FDA nod for twice-yearly HIV drug Yeztugo boosts its HIV franchise and growth outlook.

Lenacapavir, the first FDA-approved, twice-yearly injectable PrEP for HIV prevention, shows 96% efficacy and offers ...

Lenacapavir prevents spread and infection in individuals that have access to the drug. However, it cannot undo the ...

The Global Fund (GF) has significantly reduced its health financial support to Kenya, just months after the US government ...

Gilead and its partners' efforts to distribute generic lenacapavir could be derailed by cuts in international aid budgets ...